The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non‐small cell lung cancer: A systematic analysis and meta‐analysis based on randomized controlled trials-论文-万方医学网

首页> > The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non‐small cell lung cancer: A systematic analysis and meta‐analysis based on randomized controlled trials

The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non‐small cell lung cancer: A systematic analysis and meta‐analysis based on randomized controlled trials

导出原文传递

翻译打印收藏纠错

第一作者： Qiangyun Liu

作者： Qiangyun Liu ^[1] ; Zige Fang ^[2] ; Miaowen Liu ^[3] ; Ruoxin Xu ^[4] ; Fengming Yi ; Yiping Wei ; Linxiang Zeng ; Wenxiong Zhang

作者单位： Department of Thoracic Surgery,The Second Affiliated Hospital of Nanchang University ^[1] Jiangxi medical college,Nanchang University ^[2] Department of Oncology,The Second Affiliated Hospital of Nanchang University ^[3] Department of Emergency and Critical Care Medicine,The Second Affiliated Hospital of Nanchang ^[4]

关键词 CTLA4 inhibitor meta‐analysis non‐small cell lung cancer PD1/PDL1 inhibitor systematic analysis

发布时间 2022-04-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non‐small cell lung cancer: A systematic analysis and meta‐analysis based on randomized controlled trials

相似文献

同项目论文

相关期刊

检索历史 清除

The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non‐small cell lung cancer: A systematic analysis and meta‐analysis based on randomized controlled trials

相似文献

同项目论文

相关期刊

检索历史清除